VC Deals: Drug maker's 2nd round brings in 35 million

By Jack Davis, Mercury News - KAI Pharmaceuticals raised $35 million in a second round of venture funding led by new investors Aberdare Ventures and Investor Growth Capital. Also participating in the round were the company's existing investors, Skyline Ventures, InterWest Partners, Intersouth Partners, Delphi Ventures, Thomas Weisel Venture Partners and MDS Capital.

The South San Francisco company is developing therapeutics addressing acute cardiovascular disease, among other conditions, by targeting enzymes within a specific protein family.